A study published recently in Medicine (Baltimore) assessed the efficacy and safety of a combination of high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections. In all, 90 women diagnosed with subclinical or latent HPV infection received topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. Treatment was given once daily for 4 weeks. Researchers measured the HPV titer immediately and 4, 8, and 12 weeks after treatment in order to ascertain the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated. Immediately and 4, 8, and 12 weeks following treatment, HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination treatments were significantly effective against both low-risk and high-risk HPV infections. The cure rates for vaginitis and cervicitis were significantly higher in the high- vs. the low-dose IFN group. The rates were even higher in the combination group compared to the high-dose IFN group. A very small subset of patients (3/30) in the combination group reported having mild adverse effects. Combination high-dose IFN and red light therapy was found to be safe and effective against subclinical and latent HPV infections.